Cellular Senescence-Related Long Non-coding RNA Signatures Predict Prognosis in Juvenile Osteosarcoma

Overview

Journal Phenomics

Publisher Springer

Date 2024 Dec 26

PMID 39723224

Authors

Peng Zhao

Junli Chang

YeKai Chen

Xingyuan Sun

Xiaoping Ma

Chujie Zhou

Lei Zhou

Yongjun Wang

Yanping Yang

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma is the most common malignant bone tumor and is frequently diagnosed in juvenile. Cellular senescence is a fundamental hallmark of osteosarcoma and plays a vital role in the initiation and progression of aging and tumorigenesis. Long non-coding RNAs (lncRNAs) are implicated in tumorigenesis. In this study, six cellular senescence-related lncRNAs with independent prognostic significance in juvenile osteosarcoma patients were identified through univariate Cox regression analysis, least absolute shrinkage and selection operator (LASSO) regression analysis, and multivariate Cox regression analysis. Prognostic significance was further confirmed by Kaplan-Meier (KM) survival curves, co-expression interaction networks, and sankey diagrams. A prognostic model of cellular senescence-related genes in juvenile osteosarcoma patients was then constructed using multivariate Cox regression analysis based on these six genes. High- and low-risk groups were identified according to the median risk score calculated by the prognostic model. The favorable prognostic significance of this model was demonstrated through survival curves, receiver operating characteristic (ROC) curves, distribution scatter plots and lncRNA expression heatmaps. Furthermore, cellular senescence-related lncRNAs were validated by enrichment analysis, immunological correlation analysis, mA correlation analysis, and drug sensitivity correlation analysis. These findings are important for improving the prognosis of juvenile osteosarcoma patients and understanding the mechanisms underlying cellular senescence in juvenile osteosarcoma development.

References

Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K . MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010; 9(7):1956-67. DOI: 10.1158/1535-7163.MCT-09-1012. View

Wan D, Han X, Zhang C, Zhang Y, Ma Y, Wang G . EZH2 promotes the progression of osteosarcoma through the activation of the AKT/GSK3β pathway. Clin Exp Pharmacol Physiol. 2022; 49(11):1179-1186. DOI: 10.1111/1440-1681.13701. View

Lopez-Otin C, Blasco M, Partridge L, Serrano M, Kroemer G . Hallmarks of aging: An expanding universe. Cell. 2023; 186(2):243-278. DOI: 10.1016/j.cell.2022.11.001. View

Herman M, Martinek M . The limping child. Pediatr Rev. 2015; 36(5):184-95. DOI: 10.1542/pir.36-5-184. View

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

Hall A . The cytoskeleton and cancer. Cancer Metastasis Rev. 2009; 28(1-2):5-14. DOI: 10.1007/s10555-008-9166-3. View

Hanahan D . Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022; 12(1):31-46. DOI: 10.1158/2159-8290.CD-21-1059. View

Martinelli M, Mancarella C, Scapoli L, Palmieri A, De Sanctis P, Ferrari C . Polymorphic variants of and have an impact on predisposition and/or progression of Ewing sarcoma. Front Oncol. 2022; 12:968884. PMC: 9634078. DOI: 10.3389/fonc.2022.968884. View

Klein M, Siegal G . Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol. 2006; 125(4):555-81. DOI: 10.1309/UC6K-QHLD-9LV2-KENN. View

10.

Liu B, Feng C, Liu Z, Tu C, Li Z . A novel necroptosis-related lncRNAs signature effectively predicts the prognosis for osteosarcoma and is associated with immunity. Front Pharmacol. 2022; 13:944158. PMC: 9465333. DOI: 10.3389/fphar.2022.944158. View

11.

Roy A, Sierra F, Howcroft K, Singer D, Sharpless N, Hodes R . A Blueprint for Characterizing Senescence. Cell. 2020; 183(5):1143-1146. PMC: 8364378. DOI: 10.1016/j.cell.2020.10.032. View

12.

Biber G, Ben-Shmuel A, Sabag B, Barda-Saad M . Actin regulators in cancer progression and metastases: From structure and function to cytoskeletal dynamics. Int Rev Cell Mol Biol. 2020; 356:131-196. DOI: 10.1016/bs.ircmb.2020.05.006. View

13.

Sturm G, Finotello F, Petitprez F, Zhang J, Baumbach J, Fridman W . Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics. 2019; 35(14):i436-i445. PMC: 6612828. DOI: 10.1093/bioinformatics/btz363. View

14.

Mattick J, Amaral P, Carninci P, Carpenter S, Chang H, Chen L . Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023; 24(6):430-447. PMC: 10213152. DOI: 10.1038/s41580-022-00566-8. View

15.

Sharpless N, Sherr C . Forging a signature of in vivo senescence. Nat Rev Cancer. 2015; 15(7):397-408. DOI: 10.1038/nrc3960. View

16.

Ignatz-Hoover J, Murphy E, Driscoll J . Targeting Proteasomes in Cancer and Infectious Disease: A Parallel Strategy to Treat Malignancies and Microbes. Front Cell Infect Microbiol. 2022; 12:925804. PMC: 9302482. DOI: 10.3389/fcimb.2022.925804. View

17.

Coppe J, Desprez P, Krtolica A, Campisi J . The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010; 5:99-118. PMC: 4166495. DOI: 10.1146/annurev-pathol-121808-102144. View

18.

Krizhanovsky V, Xue W, Zender L, Yon M, Hernando E, Lowe S . Implications of cellular senescence in tissue damage response, tumor suppression, and stem cell biology. Cold Spring Harb Symp Quant Biol. 2009; 73:513-22. PMC: 3285266. DOI: 10.1101/sqb.2008.73.048. View

19.

Hernandez-Segura A, Nehme J, Demaria M . Hallmarks of Cellular Senescence. Trends Cell Biol. 2018; 28(6):436-453. DOI: 10.1016/j.tcb.2018.02.001. View

20.

Kang T, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D . Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 2011; 479(7374):547-51. DOI: 10.1038/nature10599. View